Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...

We recently compiled a list of Morgan Stanley’s Best Stock Picks: 15 Stocks To Own For 2025. In this article, we are going to ...

Company is investing $2.8bn in two Irish plants to produce its in-demand weight loss drugs and a new Alzheimer’s therapy ...

Lilly clearly has an abundance of growth drivers -- and the list includes more than Mounjaro, Zepbound, and the six drugs ...

Eli Lilly’s experimental insulin that is injected just once a week is as effective as daily insulin injections for ...

Full-service independent pharmaceutical marketing and communications agency RevHealth, a 2024 MM+M Agency 100 honoree, named former 21Grams and Wunderman Thompson Health exec William Martino as chief ...

Company ups manufacturing investment in Limerick by $1 billion; unveils new $800 million Kinsale facility New investment will enhance global medicine production, benefiting millions of patients ...

It cites the commercial real estate cap rate ... (see more details here). Eli Lilly and Company (NYSE:LLY) is one of the hottest stocks these days due to its commanding presence in the weight ...

The agency alleges CVS’s Caremark, Cigna’s Express Scripts and UnitedHealth’s Optum Rx accepted money from drugmakers in ...

Eli Lilly (NYSE: LLY) stands atop the biopharmaceutical ... Lilly's pipeline features several late-stage candidates that should have major commercial potential. The company is evaluating ...